NEW YORK, May 21 (Reuters) - Abbott Laboratories Inc said on Wednesday its Humira medicine has maintained maximum effectiveness for a year or longer among roughly 29 percent of Crohn's disease ...
The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...
AbbVie has been following a dependable playbook as it develops its young immunology blockbuster Rinvoq, a follow-up to its aging Humira. Relatively early in its life cycle, five years after it hit the ...
An open-label extension study of the Charm and Gain studies, performed in Abbott labs, demonstrate that patients with moderate-to-severe Crohn's disease who are treated with Humira (adalimumab) ...
As AbbVie comes under renewed scrutiny for its pricing and patenting strategies, the company is still working to build out the case for its next-gen immunology drugs Skyrizi and Rinvoq. In Crohn's ...
SAN FRANCISCO (MarketWatch) -- Abbott said Thursday the European Commission has granted marketing authorization for Humira as a treatment for severe Crohn's disease. The announcement follows the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback